IFITM1 Antibody Blocking Peptide

IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm， permitting endocytosis， but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses， including influenza A virus， SARS coronaviruses (SARS-CoV and SARS-CoV-2， Marburg virus (MARV， Ebola virus (EBOV， Dengue virus (DNV， West Nile virus (WNV， human immunodeficiency virus type 1 (HIV-1 and hepatitis C virus (HCV. Can inhibit: influenza virus hemagglutinin protein-mediated viral entry， MARV and EBOV GP1，2-mediated viral entry and SARS-CoV and SARS-CoV-2 S protein-mediated viral entry. Also implicated in cell adhesion and control of cell growth and migration. Inhibits SARS-CoV-2 S protein-mediated syncytia formation. Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activation or by arresting cell growth in G1 phase in a p53-dependent manner. Acts as a positive regulator of osteoblast differentiation. I